Hospital
Kaleida Health
Kaleida Health was paid $11.67M by Medicaid between Oct 2018 and Dec 2024, across 152 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoKALEIDA HEALTH
WILLIAMSVILLE, NY 14221
WILLIAMSVILLE, NY 14221
33aNPI1053441907assigned 03/07/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.67M
24GClaims205,789
24DCodes billed152
24AFirst – last monthOct 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#76 of 231
Median peer was paid$561K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 77 | $3K | |
| 2019 | 5,899 | $210K | |
| 2020 | 12,163 | $648K | |
| 2021 | 33,596 | $2.16M | |
| 2022 | 49,331 | $2.96M | |
| 2023 | 59,687 | $3.21M | |
| 2024incomplete | 45,036 | $2.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 8,191 | 7,813 | $1.43M |
| G0378 | Hospital observation service, per hour | 11% | 965 | 924 | $1.32M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.1% | 5,549 | 5,301 | $1.06M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.0% | 4,840 | 4,326 | $1.05M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.6% | 4,643 | 4,500 | $769K |
| 52000 | 6.0% | 544 | 544 | $703K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.0% | 1,975 | 1,933 | $589K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.9% | 4,102 | 3,999 | $457K |
| 80053 | Comprehensive metabolic panel | 3.0% | 17,909 | 16,223 | $352K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.3% | 493 | 486 | $269K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 1,001 | 987 | $262K |
| 59025 | Fetal non-stress test | 2.2% | 1,029 | 866 | $258K |
140 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.1% | 1,341 | $244K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 787 | $236K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 1,449 | $220K |
| 93975 | 1.9% | 360 | $217K | |
| 96415 | 1.8% | 505 | $208K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.7% | 1,975 | $197K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 794 | $150K |
| 95251 | 1.3% | 892 | $150K | |
| 87631 | 1.2% | 2,589 | $136K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.0% | 161 | $117K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 331 | $96K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,362 | $71K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 669 | $66K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,692 | $60K |
| 86900 | <1% | 2,619 | $59K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 675 | $54K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 277 | $50K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 386 | $42K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 424 | $42K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,392 | $38K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,325 | $37K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,432 | $35K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,191 | $34K |
| 86850 | <1% | 2,612 | $34K | |
| 86901 | <1% | 2,590 | $34K | |
| 88307 | <1% | 481 | $32K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,922 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,593 | $30K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,516 | $30K |
| 96367 | <1% | 519 | $29K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,093 | $25K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 738 | $24K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 131 | $19K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,690 | $18K |
| 81025 | <1% | 5,098 | $17K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 27 | $16K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 327 | $16K |
| 82803 | <1% | 576 | $16K | |
| 82948 | <1% | 3,974 | $15K | |
| 97161 | <1% | 188 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,493 | $12K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 291 | $11K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 89 | $9K |
| 83880 | <1% | 335 | $9K | |
| 99457 | <1% | 57 | $8K | |
| 85730 | <1% | 1,925 | $8K | |
| 85027 | <1% | 2,686 | $8K | |
| 80061 | Lipid panel | <1% | 1,015 | $8K |
| 88342 | <1% | 177 | $8K | |
| 85610 | <1% | 3,304 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 286 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,836 | $6K |
| 84439 | <1% | 731 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,565 | $5K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 251 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 136 | $5K |
| 84703 | <1% | 1,921 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,151 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 160 | $4K |
| 88304 | <1% | 245 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 100 | $4K |
| 81001 | <1% | 4,942 | $4K | |
| 96376 | <1% | 756 | $4K | |
| 70496 | <1% | 12 | $3K | |
| 99443 | <1% | 37 | $3K | |
| 97803 | <1% | 90 | $3K | |
| 96417 | <1% | 378 | $3K | |
| 83690 | <1% | 2,039 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 169 | $2K |
| 93017 | <1% | 25 | $2K | |
| 83605 | <1% | 1,140 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 64 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $2K |
| C9399 | Unclassified drugs or biologicals | <1% | 470 | $1K |
| 97162 | <1% | 14 | $1K | |
| 83874 | <1% | 1,426 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12 | $1K |
| 83735 | <1% | 1,254 | $1K | |
| 84484 | <1% | 2,540 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 54 | $1K |
| 88313 | <1% | 85 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 28 | $1K |
| 85008 | <1% | 124 | $1K | |
| 97802 | <1% | 32 | $989.41 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,791 | $918.31 |
| C1769 | Guide wire | <1% | 170 | $842.83 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,967 | $758.12 |
| 84702 | <1% | 215 | $592.79 | |
| 96411 | <1% | 19 | $585.00 | |
| 86141 | <1% | 119 | $583.36 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 743 | $447.53 |
| 87088 | <1% | 158 | $379.57 | |
| 82570 | <1% | 86 | $337.55 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,151 | $335.85 |
| 81003 | <1% | 580 | $315.04 | |
| 87070 | <1% | 270 | $289.74 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,305 | $276.48 |
| 93971 | <1% | 13 | $271.97 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,115 | $267.65 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,805 | $257.67 |
| 97010 | <1% | 31 | $253.89 | |
| 87040 | <1% | 266 | $234.45 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 546 | $199.74 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 42 | $191.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,275 | $166.87 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,244 | $163.77 |
| 82043 | <1% | 25 | $141.70 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,365 | $133.80 |
| 87147 | <1% | 12 | $112.06 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,440 | $107.75 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,254 | $97.81 |
| 85379 | <1% | 287 | $80.69 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 514 | $80.34 |
| 87077 | <1% | 27 | $73.98 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,598 | $73.44 |
| 85651 | <1% | 56 | $71.02 | |
| 87186 | <1% | 16 | $40.57 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $39.20 |
| 84100 | <1% | 16 | $37.38 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 237 | $28.26 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 56 | $19.20 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,270 | $17.49 |
| 87430 | <1% | 27 | $10.74 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 58 | $8.19 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 139 | $5.11 |
| 86308 | <1% | 12 | $5.04 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 29 | $2.52 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 187 | $2.24 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 143 | $1.89 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 122 | $0.50 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 40 | $0.00 |
| 86710 | 0% | 14 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 15 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 13 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 146 | $0.00 |
| 74018 | 0% | 14 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 252 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 53 | $0.00 |
| 87400 | 0% | 13 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCROREY, ANGELA (AR MANAGER)
Parent organizationKALEIDA HEALTH
| Provider | Location | Paid |
|---|---|---|
| Kaleida Health | Buffalo, NY | $80.65M |
| Kaleida Health | Buffalo, NY | $30.80M |
| Kaleida Health | North Tonawanda, NY | $5.40M |
| Kaleida Health | Buffalo, NY | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.